Join
Live feed
·
PRReleasevia Quantisnow
Palvella Therapeutics Inc. logo

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

ByQuantisnow·Wall Street's wire, on your screen.
PVLA· Palvella Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PVLA (Palvella Therapeutics Inc.) and more on Quantisnow.